# Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

> **NCT01548482** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Adult Solid Neoplasm
- Lung Carcinoid Tumor
- Recurrent Digestive System Neuroendocrine Tumor G1
- Recurrent Renal Cell Carcinoma
- Recurrent Uterine Corpus Sarcoma
- Stage III Renal Cell Cancer
- Stage IIIB Uterine Sarcoma
- Stage IIIC Uterine Sarcoma
- Stage IV Renal Cell Cancer
- Stage IVA Uterine Sarcoma
- Stage IVB Uterine Sarcoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Temsirolimus
- **BIOLOGICAL:** Trebananib

## Key facts

- **NCT ID:** NCT01548482
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01548482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01548482, "Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT01548482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*